Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study

Published:September 03, 2022DOI:


      • High-risk smoldering presents a 50% progression risk to active myeloma at 2 years.
      • Early treatment has demonstrated to delay the progression to myeloma.
      • Rd confirms the sustained benefit in TTP and OS in high-risk smoldering.
      • Many trials are ongoing to support the role of early detection and intervention.



      Smoldering multiple myeloma (SMM) is a heterogeneous disease in terms of progression to myeloma (MM), but its standard of care continues to be observation.


      The QuiRedex phase 3 trial initiated in 2007 included 119 high-risk patients with SMM randomized to treatment or observation. Treatment consisted of nine 4-week induction cycles (lenalidomide [Rd], 25 mg on days 1–21 plus dexamethasone, 20 mg on days 1–4 and 12–15), followed by maintenance (R, 10 mg on days 1–21) for up to 2 years. The primary end-point was time to progression (TTP) to myeloma based on per protocol population. Secondary end-points were overall survival (OS), response rate, and safety. An update of the trial after a long-term follow-up is presented here. This trial was registered with (NCT00480363).


      After a median follow-up time of 12.5 years (range: 10.4–13.6), the median TTP to MM was 2.1 years in the observation arm and 9.5 years in the Rd arm (HR: 0.28, 95% CI: 0.18–0.44, p < 0.0001). The median OS was 8.5 years in the abstention arm and not reached in the Rd group (HR: 0.57, 95% CI: 0.34–0.95, p = 0.032). Patients who progressed received optimized treatments according to the standards of care, and the OS from progression was comparable in both arms (p = 0.96).


      This analysis confirms that early treatment with Rd for high-risk SMM translates into a sustained benefit in both TTP and OS.


      Pethema (Spanish Program for the Treatment of Hematologic Diseases), Spain.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Rajkumar S.V.
        • Dimopoulos M.A.
        • Palumbo A.
        • et al.
        International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
        Lancet Oncol. 2014; 15: e538-e548
        • International Myeloma Working Group
        Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group.
        Br J Haematol. 2003; 121: 749-757
        • Kyle R.A.
        • Remstein E.D.
        • Therneau T.M.
        • et al.
        Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.
        N Engl J Med. 2007; 356: 2582-2590
        • Pérez-Persona E.
        • Mateo G.
        • García-Sanz R.
        • et al.
        Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells.
        Br J Haematol. 2010; 148: 110-114
        • Mateos M.V.
        • Hernández M.T.
        • Giraldo P.
        • et al.
        Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.
        N Engl J Med. 2013; 369: 438-447
        • Mateos M.V.
        • Hernández M.T.
        • Giraldo P.
        • et al.
        Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up a randomised, controlled, phase 3 trial.
        Lancet Oncol. 2016; 17: 1127-1136
        • Durie B.G.
        • Harousseau J.L.
        • Miguel J.S.
        • et al.
        International uniform response criteria for multiple myeloma.
        Leukemia. 2006; 20: 1467-1473
        • Pulte D.
        • Jansen L.
        • Brenner H.
        Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century.
        Blood Cancer J. 2020; 10: 56
        • Lonial S.
        • Jacobus S.
        • Fonseca R.
        • et al.
        Randomized trial of lenalidomide versus observation in smoldering multiple myeloma.
        J Clin Oncol. 2020; 38: 1126-1137
        • Mateos M.V.
        • Kumar S.
        • Dimopoulos M.A.
        • et al.
        International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM).
        Blood Cancer J. 2020; 10: 102
        • Garcés J.J.
        • Puig N.
        • Termini R.
        • et al.
        Circulating tumor cells (CTCs) in smoldering and active multiple myeloma (MM): mechanism of egression, clinical significance and therapeutic endpoints.
        Blood. 2021; 138: 76
        • Bustoros M.
        • Sklavenitis-Pistofidis R.
        • Park J.
        • et al.
        Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression.
        J Clin Oncol. 2020; 38: 2380-2389
        • Kazandjian D.
        • Hill E.
        • Morrison C.
        • et al.
        Treatment of high risk (HR) smoldering multiple myeloma (SMM) with carfilzomib, lenalidomide, and dexamethasone (KRd) followed by lenalidomide maintenance (–R): a phase 2 clinical and correlative study.
        Blood. 2020; 136: 43-45
        • Bustoros M.
        • Liu C.
        • Reyes K.
        • et al.
        Phase II trial of the combination of ixazomib, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma.
        Blood. 2018; 132: 804-814
        • Liu C.
        • Ghobrial I.M.
        • Bustoros M.
        • et al.
        Phase II trial of combination of elotuzumab, lenalidomide, and dexamethasone in high-risk smoldering multiple myeloma.
        Blood. 2018; 132: 154
        • Landgren C.O.
        • Chari A.
        • Cohen Y.C.
        • et al.
        Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (Centaurus).
        Leukemia. 2020; 34: 1840-1852
        • Manasanch E.E.
        • Jagannath S.
        • Lee H.C.
        • et al.
        A multicenter phase II single arm trial of isatuximab in patients with high risk smoldering multiple myeloma (HRSMM).
        Blood. 2019; 134: 3116
        • Mohty M.
        • Avet-Loiseau H.
        • Harousseau J.L.
        Requirements for operational cure in multiple myeloma.
        Blood. 2021; 138: 1406-1411
        • Mateos M.-V.
        • Martinez-Lopez J.
        • Rodriguez Otero P.
        • et al.
        Curative strategy (GEM-CESAR) for high-risk smoldering myeloma (SMM): carfilzomib, lenalidomide and dexamethasone (KRd) as induction followed by HDT-ASCT, consolidation with Krd and maintenance with Rd.
        Blood. 2019; 134: 781
        • Kumar S.K.
        • Abdallah A.-O.
        • Badros A.Z.
        • et al.
        Aggressive smoldering curative approach evaluating novel therapies (ASCENT): a phase 2 trial of induction, consolidation and maintenance in subjects with high risk smoldering multiple myeloma (SMM): initial analysis of safety data.
        Blood. 2020; 136: 35-36